{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:41Z","timestamp":1793134121686,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017037","name":"Cepheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003417","name":"German Social Accident Insurance","doi-asserted-by":"publisher","award":["FB-0241"],"award-info":[{"award-number":["FB-0241"]}],"id":[{"id":"10.13039\/501100003417","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013936","name":"Medical Research Foundation at the University Hospital Erlangen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013936","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.020","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:09:22Z","timestamp":1746605362000},"page":"1041-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low\/Intermediate-risk Bladder Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Bernd J.","family":"Schmitz-Dr\u00e4ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehardt","family":"Bismarck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"von Landenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Noldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Kernig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Hakenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hennenlotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Erne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Rowinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Schiffhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Baranek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Benderska-S\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.020_b0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.020_b0010","unstructured":"Gontero P, Birtle A, Comp\u00e9rat E, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer."},{"key":"10.1016\/j.euo.2025.04.020_b0015","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/ajhp\/zxaa270","article-title":"Evaluation of post-flexible cystoscopy urinary tract infection rates","volume":"77","author":"Cusumano","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.euo.2025.04.020_b0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.020_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-211602","article-title":"Commentary: Sensitivity and specificity in urine bladder cancer markers \u2013 Is it that simple?","volume":"8","author":"Roghmann","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.04.020_b0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.urolonc.2020.01.006","article-title":"Towards non-invasive follow-up of low risk bladder cancer \u2013 rationale and concept of the UroFollow trial","volume":"12","author":"Benderska-S\u00f6der","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.020_b0035","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.01 (Konsultationsfassung), 2019, AWMF-Registrierungsnummer 032\/038OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom\/."},{"key":"10.1016\/j.euo.2025.04.020_b0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2025.04.020_b0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jasc.2016.04.005","article-title":"The Paris System for Reporting Urinary Cytology: the quest to develop a standardized terminology","volume":"5","author":"Barkan","year":"2016","journal-title":"Am Soc Cytopathol"},{"key":"10.1016\/j.euo.2025.04.020_b0050","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.euf.2022.02.006","article-title":"Reducing the frequency of follow-up cystoscopy in low-grade pTa non\u2013muscle-invasive bladder cancer using the ADXBLADDER biomarker","volume":"8","author":"Roupret","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.04.020_b0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.juro.2009.08.150","article-title":"Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial","volume":"183","author":"van der Aa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.04.020_b0060","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2008.05.001","volume":"55","author":"van der Aa","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.020_b0065","unstructured":"Jensen JB. Surveillance of high-grade non-muscle invasive bladder tumours using the Xpert bladder cancer monitor (SEALS Xpert). https:\/\/ichgcp.net\/clinical-trials-registry\/NCT04100733."},{"key":"10.1016\/j.euo.2025.04.020_b0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.urolonc.2024.01.025","article-title":"Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer","volume":"42","author":"Benderska-S\u00f6der","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.020_b0075","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.urolonc.2013.10.010","article-title":"Considerations on the use of urine markers in the management of patients with low-\/intermediate-risk non-muscle invasive bladder cancer","volume":"32","author":"Schmitz-Dr\u00e4ger","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.020_b0080","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bju.13536","article-title":"Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project","volume":"118","author":"Hurle","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.04.020_b0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","article-title":"Long-term follow-up and factors associated with active surveillance failure for patients with non-muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance (BIAS) experience","volume":"5","author":"Contieri","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.020_b0090","doi-asserted-by":"crossref","first-page":"27.e1","DOI":"10.1016\/j.urolonc.2012.09.011","article-title":"Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer","volume":"32","author":"Yafi","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.020_b0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/MOU.0000000000000545","article-title":"Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?","volume":"28","author":"Soria","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2025.04.020_b0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00345-022-04253-3","article-title":"Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review","volume":"41","author":"Soorojebally","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.04.020_b0105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.020_b0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bju.14019","article-title":"Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance","volume":"121","author":"Pichler","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.04.020_b0115","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncy.22152","article-title":"Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non\u2013muscle-invasive bladder cancer","volume":"127","author":"Trenti","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.euo.2025.04.020_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756287221997183","article-title":"Diagnostic value of Xpert bladder cancer monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update","volume":"13","author":"D\u2019Elia","year":"2021","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euo.2025.04.020_b0125","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00420-013-0916-3","article-title":"UroScreen Study Group. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines","volume":"87","author":"Pesch","year":"2014","journal-title":"Int Arch Occup Environ Health"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:26:21Z","timestamp":1762629981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001154"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.020","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low\/Intermediate-risk Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}